Hormonal IUD (Mirena/Kyleena) Side Effects, Withdrawal & Discontinuation Syndrome

What Hormonal IUDs Actually Do Inside Your Body

Levonorgestrel IUDs work primarily at the level of the uterine cervix and endometrium. They thicken cervical mucus, thin the uterine lining, and suppress ovulation partially (more so with the higher-dose 52 mg Mirena than with the 19.5 mg Kyleena). They do not reliably stop ovulation in all cycles, which is why many women continue to experience cycle-related symptoms even while using one.

Systemic absorption is real, not negligible. Mirena's prescribing label reports mean plasma levonorgestrel concentrations of roughly 150-200 pg/mL in the first month, falling to around 100 pg/mL by year five. Kyleena reaches lower systemic levels, approximately 70 pg/mL initially per its FDA label. These concentrations are lower than most progestin-only pills but not zero. That systemic fraction is why some women notice hormonal effects in skin, mood, libido, and headache patterns.

How Ovarian Function Is Affected

Because Mirena's higher dose can partially suppress the hypothalamic-pituitary-ovarian (HPO) axis, some women have anovulatory cycles with lower estrogen troughs than usual. This is relevant if you are already in perimenopause, where your estrogen levels are already declining. Your clinician may not automatically distinguish perimenopausal symptoms from IUD-related hormonal effects. Knowing that the device can blunt the mid-cycle LH surge is useful context for interpreting mood or libido changes that appear mid-cycle.

Sex-Specific Pharmacology Worth Knowing

Women metabolize progestins differently across the menstrual cycle and across life stages. Body fat percentage, which is on average higher in women than in men, influences the volume of distribution for lipophilic progestins like levonorgestrel. A pharmacokinetic review published in the journal Contraception found that serum LNG levels in IUD users varied nearly three-fold between individuals, meaning that "low systemic exposure" is an average, not a guarantee for every woman.

The Most Common Side Effects by Life Stage

Most side effects are front-loaded in the first three to six months and improve over time. Still, about 15% of women discontinue hormonal IUDs within the first year because of bleeding irregularities or pain, and that rate rises in specific subgroups.

Reproductive Years (Ages 18-40)

Irregular bleeding. The most reported early side effect. Spotting or unpredictable light bleeding is very common in the first three months. By six months, up to 20% of Mirena users become amenorrheic, which many women welcome but which can feel alarming without preparation.

Hormonal acne. Levonorgestrel binds the androgen receptor and has measurable androgenic activity. This is a meaningful difference from progestins like drospirenone (which is anti-androgenic) or from the copper IUD (which is progestin-free). If you switched from a combined oral contraceptive with an anti-androgenic progestin to a hormonal IUD, you may notice acne or increased oiliness, sometimes within weeks.

Mood and depression. This is the most contested area. A widely cited Danish cohort study of over one million women found that hormonal contraceptive use was associated with a higher rate of first antidepressant use, with the progestin-only IUD showing a relative risk of approximately 1.4 for antidepressant use compared to non-users. Critics note the study was observational and could not rule out confounding. A 2023 systematic review in AJOG found the evidence on progestin-only methods and depression to be inconsistent across study designs. The honest answer: a causal link is plausible, given that progesterone receptor activity in the brain affects GABA and serotonin pathways, but not definitively established in IUD-specific data.

Libido changes. Lower SHBG (sex hormone-binding globulin) is expected with any progestin, which should theoretically free up more testosterone. In practice, some women report decreased libido with hormonal IUDs, possibly mediated by partial suppression of midcycle testosterone peaks or by mood effects.

Headaches. Hormonal headaches can worsen in the first few months. Women with menstrual migraine should be aware that changes in their cycle pattern may alter their migraine trigger pattern, not necessarily for the worse, but predictably differently.

Perimenopause (Ages 40-52 Typically)

The LNG-IUD 52 mg (Mirena) is endorsed by ACOG as an effective option for managing heavy menstrual bleeding in perimenopause and as the progestogen component of menopausal hormone therapy when combined with systemic estrogen. This is a meaningful therapeutic use beyond contraception.

In perimenopause, distinguishing IUD side effects from natural hormonal fluctuations is genuinely difficult. Hot flashes, night sweats, mood shifts, and brain fog that emerge while you have a hormonal IUD in place may reflect declining ovarian function, not the device. The IUD itself does not supply estrogen, so it will not prevent vasomotor symptoms.

Nulliparous Women (Never Given Birth)

Insertion is more painful in women who have not had a vaginal delivery, and the risk of expulsion is modestly higher. A large multicenter trial (the APEX IUD study) found expulsion rates of approximately 8% in nulliparous women compared to roughly 4% in parous women over three years. Cramping after insertion can be severe and last 24-48 hours. Misoprostol pretreatment for cervical softening is not routinely recommended by ACOG based on current evidence but is sometimes used off-label.

Rare but Real Side Effects

Most adverse event data on LNG-IUDs comes from the FDA Adverse Event Reporting System (FAERS) and from large observational registries rather than from placebo-controlled trials (which are ethically difficult to design for contraceptive devices). That means rare side effects are harder to causally attribute, and the evidence base is thinner than for orally dosed drugs. Naming that limitation is more useful to you than overstating certainty.

Ovarian cysts. Functional ovarian cysts occur in approximately 12% of Mirena users per the prescribing label. Most resolve spontaneously within one to two months without intervention.

Pelvic inflammatory disease (PID). Risk is highest in the first 20 days after insertion and is related to the insertion procedure introducing bacteria, not to ongoing IUD use. The WHO Medical Eligibility Criteria notes that after the first month, the background PID risk in IUD users is not significantly elevated above baseline in women without sexually transmitted infections.

Uterine perforation. A rare but serious complication occurring in approximately 1-2 per 1,000 insertions. Risk is higher in postpartum women who are breastfeeding, where the uterus is more involuted and softer. ACOG recommends waiting at least four weeks postpartum before insertion to reduce perforation risk.

Pseudotumor cerebri (idiopathic intracranial hypertension). There are case reports in the FAERS database linking progestin-containing devices to elevated intracranial pressure. The absolute risk appears very low, and causality is not established, but women who develop new-onset headaches with visual changes or pulsatile tinnitus after IUD placement should be evaluated promptly.

Hair loss (telogen effluvium). Some women report diffuse hair shedding, likely related to the androgenic activity of levonorgestrel. This is not listed prominently in the prescribing label but appears repeatedly in patient forums and in some FAERS filings. Formally studied data in IUD users specifically are sparse; most evidence extrapolates from systemic progestin studies.

Withdrawal and Discontinuation Syndrome: What the Evidence Actually Shows

"IUD withdrawal syndrome" is a term circulating widely on social media and in patient communities. The clinical literature has not validated it as a formal syndrome in the way that SSRI discontinuation syndrome is characterized. That gap between patient experience and published evidence deserves a direct look.

What Women Report After Removal

After Mirena or Kyleena removal, many women describe a cluster of symptoms in the days to weeks following: mood dips, anxiety, fatigue, skin changes (acne flares or oiliness), temporary worsening of headaches, and return of heavy or painful periods. These reports are consistent and repeated across patient communities, which gives them clinical credibility even in the absence of controlled trial data.

The Physiological Explanation

When the device is removed, circulating LNG levels fall quickly, since the half-life of levonorgestrel is approximately 24-36 hours. If the device was partially suppressing ovarian function, the HPO axis must recalibrate. During that window, estrogen and progesterone levels may fluctuate before settling into a regular ovulatory pattern. This recalibration period is biologically real. Whether it constitutes a "syndrome" with a predictable timeline and symptom cluster is not yet established in prospective data.

A 2022 review in Contraception examining post-discontinuation experiences across hormonal contraceptive types found no randomized controlled trial data specifically examining LNG-IUD withdrawal symptoms as a primary endpoint. The reviewers concluded that patient-reported symptom clusters after hormonal contraceptive discontinuation are plausible mechanistically but under-studied.

How Long Symptoms May Last

Anecdotally, women report symptoms lasting anywhere from two weeks to six months. The physiological expectation based on HPO axis recovery timelines is that significant disruption should resolve within two to three cycles. Women who had irregular cycles before IUD placement may find that their original cycle pattern reasserts itself, including heavy or painful periods if those were the pre-IUD baseline.

Distinguishing Withdrawal from Underlying Conditions

If symptoms persist beyond three months post-removal, the working assumption of "IUD withdrawal" should be reconsidered. Conditions worth evaluating include: thyroid dysfunction (hypothyroidism can mimic many post-IUD symptoms including fatigue, mood changes, and heavy bleeding), PCOS that was being masked by the IUD's endometrial suppression, perimenopausal transition beginning, and iron deficiency from returning heavy periods. A TSH, CBC, and a cycle tracking log for two to three months are reasonable first steps before attributing prolonged symptoms to the device.

Pregnancy, Lactation, and Contraception: The Essential Section

During Pregnancy

The LNG-IUD is a contraceptive device, so pregnancy while the device is correctly placed is rare but possible: the Mirena label reports a failure rate of approximately 0.2% per year in clinical trials. If pregnancy occurs with the IUD in place, the device should be removed promptly because leaving it in place substantially increases the risk of septic abortion and preterm delivery. Removal itself carries a small risk of pregnancy loss (approximately 25%), but that risk is lower than the risks of leaving the device.

Levonorgestrel exposure in early unintended pregnancies with an IUD in place: the limited data available do not suggest a pattern of fetal malformation specifically attributable to LNG at these low local concentrations, but the data are insufficient to draw confident conclusions. This is a conversation to have with your OB immediately.

The LNG-IUD is classified as a contraceptive; there is no approved use during pregnancy, and systemic progestins at pharmacologic doses carry FDA Pregnancy Category X or equivalent teratogenic concern signals from older oral studies. Local IUD-level exposure is a different exposure scenario, but "different" does not mean "proven safe."

Postpartum and Lactation

The LNG-IUD is compatible with breastfeeding. The CDC US Medical Eligibility Criteria (USMEC) rates LNG-IUDs as Category 2 (benefits generally outweigh risks) for women who are less than four weeks postpartum and breastfeeding, and Category 1 (no restriction) after four weeks. Levonorgestrel does transfer into breast milk in small amounts, but the total infant dose is estimated at well under 1% of the maternal weight-adjusted dose, which is generally considered clinically insignificant. The WHO similarly classifies LNG-IUD use during lactation as acceptable.

The concern about potential suppression of milk supply with early postpartum placement (before four weeks) led to the Category 2 rating, though evidence for this effect at IUD-dose LNG levels is not strong. Women who are exclusively breastfeeding and concerned about supply may choose to wait until the four-week mark.

After Removal: Fertility Return

Fertility returns quickly after LNG-IUD removal, typically within one to three menstrual cycles. A prospective cohort study published in Contraception found that 12-month cumulative pregnancy rates after IUD removal were comparable to rates in women discontinuing barrier methods. There is no clinically meaningful fertility delay from the IUD itself.

Who This IUD Is Right For, and Who Should Think Carefully

The LNG-IUD is well-matched for women who want long-acting reversible contraception without daily adherence, women with heavy or painful periods (heavy menstrual bleeding is an FDA-approved indication for Mirena 52 mg), women in perimenopause who need both contraception and endometrial protection if adding systemic estrogen, and women with endometriosis who benefit from endometrial suppression.

Women who may want to think more carefully before choosing an LNG-IUD: those with a personal history of severe depression or mood disorders that worsened on hormonal contraceptives, those with androgen-sensitive conditions like cystic hormonal acne where the androgenic progestin may aggravate symptoms (a copper IUD or an anti-androgenic pill may be a better fit), women with PCOS who are already experiencing androgenic symptoms, and women with a history of hormonally sensitive migraine with aura (though the IUD's low systemic exposure makes absolute risk of stroke low, the risk-benefit conversation is worth having).

Women with active cervical or uterine cancer, unexplained uterine abnormalities, current STI or PID, or known or suspected pregnancy should not use the LNG-IUD.

Managing Side Effects That Arise

For irregular bleeding in the first three to six months: expectant management is the evidence-based approach. The bleeding pattern in most women improves substantially by month six. NSAIDs taken around the time of expected bleeding can reduce spotting volume in some women, based on small studies in IUD users.

For acne that appears or worsens: if the hormonal IUD is otherwise working well for you, topical retinoids and benzoyl peroxide remain effective and are compatible with IUD use. If acne is severe, a prescribing conversation about spironolactone (which counteracts androgenic effects) is worth having with your clinician, bearing in mind that spironolactone requires reliable contraception given its feminizing effects on male fetuses, and that the IUD itself provides that contraception.

For mood symptoms: do not dismiss them as "just hormonal" without proper screening. The Edinburgh Postnatal Depression Scale or the PHQ-9 are validated tools your clinician can use. If mood symptoms are significantly affecting your quality of life, removal is a reasonable clinical choice, not a last resort.

"The absence of large prospective trials on post-LNG-IUD discontinuation symptoms is a real evidence gap, not a reason to dismiss what patients are telling us," says Rachel Goldberg, MD, OB-GYN and WomanRx medical reviewer. "When a woman says she felt significantly better within two weeks of Mirena removal, that clinical history deserves weight even if we cannot point to a published withdrawal syndrome protocol."

A Practical Timeline: What to Expect Month by Month

Months 1-3 after insertion: Irregular spotting, cramping, possible mood and skin changes. Ovarian cysts may form. This is the highest-risk window for expulsion; check your strings monthly.

Months 3-6: Bleeding usually becomes lighter and more predictable. Many women reach amenorrhea. Skin and mood effects typically stabilize if they are going to improve.

Year 1 onward: The device is functioning at a low steady-state. Side effects that persist beyond six months are less likely to self-resolve and more worth a clinical conversation.

After removal: Expect LNG levels to clear within 48-72 hours. Ovulation may return within weeks. First post-removal period typically arrives within four to eight weeks but can take up to three months.